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The Generation and Phenotypic effect of 
Human Genetic Mutations 
Chen Chen 
Mutations cause genetic variations among cells within an individual as well as variations 
between individuals within a species. It is the fuel for evolution and contributes to most 
human diseases. Despite its importance, it still remains elusive how mutagenesis and repair 
shape the mutation pattern in the human genome and how to interpret the impact of a 
mutation with respect to its ability to cause disease (referred to as pathogenicity). The 
availability of large-scale genomic data provides us an opportunity to use machine learning 
methods to answer these questions. 
This thesis is composed of two parts. In the first part, a single statistical model is 
applied to both mutations in germline and soma to compare the determinant factors that 
influence local mutation. Notably, our model revealed that one determinant, expression level, 
has an opposite effect on mutation rate in the two types of tissues. More specifically, somatic 
mutation rates decrease with expression levels and, in sharp contrast, germline mutation rates 
increase with expression levels, indicating that the DNA damage or repair processes during 
transcription differ between them. In the second part, we developed a new neural-network-
based machine learning method to predict the pathogenicity of missense variants. Besides 
predictors commonly used in previous methods, we included additional predictors at the 
variant-level such as the probability of being in protein-protein interaction interface and gene-
  
 
level such as dosage sensitivity and protein complex formation probability. To benchmark 
real-world performance, we compiled somatic mutation data in cancer and germline de novo 
mutation data in developmental disorders. Our model achieved better performance in 
prioritizing pathogenic missense variants than previously published methods. 
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Chapter 1: Introduction 
1.1 Overview 
A genetic mutation is the alteration of the nucleotide sequence of the genome of an organism. 
By its effect on genome structure, mutation can be divided into several types, substitution, 
small insertion and deletion, copy number variation and chromosomal rearrangement. The 
major focus of this thesis is substitutions.   
Substitution arises from a variety of mechanisms including spontaneous lesions, DNA 
replication errors, cellular repair processes and etc. These mechanisms occur throughout the 
genome at different rates and shape the mutation pattern together. Analyzing the regional 
mutation rates and signatures in the genome allow us to shed light on the biological processes 
that are involved and access their effects across different tissues and cell types. 
In the first part of this thesis, we investigated the mutation rate variation and by which 
mechanism it occurs in two sets of mutations, germline and somatic. Germline mutation, 
which occurs during the formation of egg and sperm and is thus present in all cells of an 
individual, underlies all evolutionary adaptations and all heritable diseases. Somatic 
mutation, which occurs post-zygotically and is thus present in only a subset of cells of an 
individual, contribute to aging and cancer. We applied the same statistical model to contrast 
the determinant factors of mutation rate between germline and soma. 
 Mutations can be also categorized by their effect on fitness into benign (including neutral 
and beneficial) and pathogenic mutations. Pathogenicity is defined as the ability of a mutation 
to cause disease at the organism level. It’s different from functional impact at the protein 
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level. For instance, both activated oncogene and deactivated repressor genes in cancer are 
considered as pathogenic in this context. Identification of risk variants and genes that 
contribute to the disease through analysis of genetic variants is one of the major goals of 
human genetics. It allows us to improve our understanding of disease etiology and help 
identify drug target. Previous studies have developed a number of computational tools to 
prioritize a large number of genetic variants found in each patient. However, existing tools do 
not achieve optimal performance for genetic analysis. Since pathogenic variants with large 
effect are typically rare and often occur in protein-coding regions1,2, I focused on rare 
missense variants among all substitutions in the second part of this thesis and developed a 
machine learning model to prioritize these variants. 
 
1.2 Mutation generation  
1.2.1 DNA damage sources and signatures 
DNA damage occurs constantly in the human genome through a variety of mechanisms. It 
may come from endogenous sources, such as spontaneous reactions, replication errors and 
reactive oxygen species (ROS) attack, as well as exogenous sources, such as UV light, 
radiation and toxic compounds. It has been estimated that around ten thousand damaging 
events occur in a mammalian genome per cell per day3,4. If not repaired, these errors will lead 
to mutations that may contribute to evolution and disease. Mutations that arise from different 
sources occur at different rates with distinct signatures. 
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Figure 1.1 DNA damage and repair mechanisms. The diagram illustrates common DNA 
damaging agents, examples of DNA lesions caused by these agents, and the relevant DNA 
repair mechanism responsible for their removal. (Adapted from Dexheimer T. 20135) 
 
Spontaneous lesions 
Spontaneous lesions include depurination, depyrimidination, deamination and etc. They all 
naturally occur in the human genome owing to the relatively low stability of the 
corresponding bases. The most frequent type, depurination, occurs at the rate of five thousand 
bases each day in a cell6. Depyrimidination occurs at a much lower rate at around five 
hundred bases per cell per day7. Deamination is even less common, the rate of which has 
been estimated to be around a hundred bases per cell per day8,9. In mammalian genome, CpG 
dinucleotides are heavily methylated except for the those in the CpG islands10,11. 
Deamination of unmethylated cytosine generates uracil which can be removed and corrected 
by the corresponding glycosylase12. However, deamination of methylated cytosine produces 
thymidine, which cannot be recognized and removed by glycosylase and thus lead to C to T 
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transition13. As a result, CpG sites outside CpG islands in the human genome are 
hypermutable, leading to over ten-fold variation in local mutation rate14.  
 
DNA replication errors 
Eukaryotic DNA polymerase replicates the genome with a very low error rate, introducing 
less than one error per ten thousand bases15. The error rate depends on the type of substitution 
and its sequence context, exhibiting over a hundred fold variation15. Despite its high 
accuracy, the incorrect nucleotide is sometimes incorporated, resulting in mismatch base 
pairs. In addition to mismatch errors, the polymerase tends to stutter when duplicating 
repetitive sequences, which leads to insertion or deletion. 
 
Cellular repair processes 
Errors sometimes cannot be repaired perfectly as the original DNA and hence can introduce a 
mutation. For instance, when non-homologous end joining (NHEJ) and micro-homology 
mediated end joining (MMHJ) is used for repair of double-strand breaks, imperfect alignment 
of short sequences on the two ends of the break are used to guide repair, which usually 
introduces deletions16. Details of these two pathways are reviewed in Lieber MR et al 2010. 
 
Induced mutations 
Mutation can be also induced by specific chemicals or radiation. Reactive oxygen species 
(ROS), the most abundant type of endogenous toxic chemicals, are generated continuously as 
the respiration byproducts of mitochondria. It can give rise to several types of DNA lesions 
including oxidized bases (Eg. 9-oxoG in Fig 1.2, which increases spontaneous G-to-T 
transversions), base loss, strand breaks, crosslinks and etc. Ultraviolet and ionizing radiation 
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(X-ray) is the major exogenous source of mutations, which leads to bulky adducts (Eg. 
cyclobutane pyrimidine dimers (CPGs) in Fig 1.2), strand breaks as well as crosslinks. In 
addition to physical sources, a variety of chemical agents have been found to induce 
mutations. For instance, the mutagenic component of tobacco smoke, benzopyrene, 
covalently bind to DNA bases to form bulky adducts and induce G-to-T transversions at CpG 
sites preferentially17. 
 
1.2.2 DNA repair pathways  
To maintain the genome integrity and ensure accurate replications of the DNA material, the 
cell has evolved several repair mechanisms to deal with different types of mutations5 (Fig 
1.2). Base excision repair (BER), mismatch repair (MMR) and nucleotide excision repair 
(NER) are major pathways responsible to fix single-strand damages, whereas non-
homologous end joining (NHEJ), homologous recombination (HR) and microhomology-
mediated end joining (MMEJ) are major pathways to resolve double-strand break.  
 
Base excision repair 
Base excision repair is responsible to repair single-base errors that do not distort the DNA 
double helix structure, including errors caused by alkylation, deamination, oxidation and lost 
bases. DNA glycosylase will remove modified bases to form abasic sites, namely apurinic or 
apyrimidinic (AP) sites. These AP sites will then be recognized and cleaved by corresponding 
glycosylase and endonuclease. DNA polymerase will then fill in the single-base gap with 
correct bases that pair with the opposite strand. 
 
  
      6 
Nucleotide excision repair 
Nucleotide excision repair (NER) can cope with more complicated damages that involve the 
distortion of the DNA molecule, such as radiation-induced pyrimidine dimers, and result in 
excision of a nucleotide patch containing the damaged sites.  It can be divided into several 
differentially regulated sub-pathways: global genome repair (GGR), transcription-coupled 
repair (TCR) (Figure 1.3), and transcription domain-associated repair (DAR). GGR occurs 
across the entire genome and throughout the cell cycle. It repairs lesions on both transcribed 
strand (TS) and non-transcribed strand (NTS), including transcribed regions as well as 
transcriptionally silent ones. TCR which is triggered by lesions encountered by the 
transcription complex and therefore repairs the TS more efficiently than the NTS. As a result, 
it leads to mutational strand asymmetry, as well as a compositional asymmetry between 
strands. For example, TCR leads to more A to G mutations on the NTS than TS which 
generates an excess of G over A on the NTS over long periods of time 18,19. 
 
 




Lesion stalls RNA Polymerase.  
Lesion/mutation repaired.
Lesion/mutation not correctly repaired.
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One of the aims of this thesis is to analyze the signature and strand bias of mutations in 
germline and soma and speculate the underlying mutagenesis and repair processes that 
generate the corresponding pattern.  
 
Mismatch repair 
The mismatch repair pathway corrects mismatch errors introduced during replication, 
including both substitutions and insertion/deletion mismatch loop. It can distinguish the 
template strand from the nascent strand and hence correct the mis-paired nucleotide on the 
latter. This pathway is essential for maintaining genome integrity after DNA replication and 
lead to an improvement in the replication fidelity by around a hundred fold20. 
 
Double strand break repair 
A potentially more damaging type of mutation is the double-strand break (DSB). This is 
usually caused by radiation, oxidization and etc. Two major repair pathways have evolved to 
correct this type of error: non-homologous end joining (NHEJ) and homologous 
recombination (HR). 
NHEJ is an error-prone repair pathway that simply re-joins the broken ends, leading to a 
deletion of a few base pairs. It occurs in all cell cycle stages. A more reliable type of repair is 
HR which occurs in late S and G2 phase only. It utilizes the sequence from the sister 
chromatid and requires recombination protein complex to find the matched sequence. MMHJ 
is also mutagenic but only occurs in S phase. It utilizes short homologous sequences during 
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1.2.3 Mutation rate variation within a genome 
Mutations identified by sequencing is the net outcome of two counteractive processes, 
mutagenesis and repair. The rate of mutation within the genome varies at different scales, 
from a single base pair to much larger scale of megabases14,22. As expected, the regional 
mutation rate has been shown to correlate with a number of factors and biological processes, 




The rate of mutation is not only determined by the single base that has been changed but also 
affected by its context. GC content shows significant positive correlation with regional 
mutation rate in human-chimpanzee divergence data, although it only accounts for around ten 
percent of the variation23,24. In addition to the nucleotide composition, the adjacent sequence 
of mutated base pair shows the effect on mutation rate. The mutation rate of C to T transitions 
at CpG sites is over ten-fold higher than that at non-CpG sites due to the spontaneous 
deamination of methylated cytosine in mammals12,25,26. With a larger amount of pedigree data 
available, studies have estimated the mutation rate variation with higher resolution, 
considering one27 or even three adjacent bases on each side28. These studies suggest that more 
data and a model considering more adjacent bases can explain a larger fraction of the 
variation at fine-scale mutation rate. 
 
Chromatin structure 
In addition to genetic features, a number of epigenetic features were shown to correlate well 
at a variety of scales with mutation rates in both cancer somatic mutations and germline 
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mutations represented by population SNP density and human-chimpanzee divergence29. One 
particular histone modification, H3K9me3, which indicates closed chromatin and repressed 
transcription, covers more than forty percent of the total variation29. An interesting finding is 
that a number of histone modifications show opposite correlation with mutation rate in 
germline and soma, indicating potential differences in the underlying causes30. An 
independent study also suggested that chromatin regions in closed form tend to have higher 
background mutation rate in germline31.  
 
Recombination rate  
DNA recombination occurs when homologous chromosomes line up and exchange the paired 
segments during meiosis or DSB repair. A positive correlation has been found between sex-
averaged DNA recombination rate and mutation rate represented by human SNP diversity 
data over bins of varying sizes, ranging from two to thirty megabase32. This is consistent with 
the fact that recombination is mutagenic, as mentioned in previous DNA repair section. 
 
DNA replication timing 
As discussed in the previous section, errors accumulated during DNA replication where 
genomic regions undergo replication at a different time during S phase. Based on divergence 
and SNP density data, the mutation rate of all types of substitutions is higher in late 
replicating region26,33. 8/10/2018 9:59:00 AMIn cancer somatic mutations, the rate of 
mutation also increases with late replication time at the scale of 100kb34. This indicates that a 
replication time-dependent mechanism is involved in generating a certain fraction of these 
mutations in both germline and soma. One existing hypothesis is that the higher mutation rate 
is due to the depletion of free nucleotides to be incorporated into newly synthesized DNA at a 
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later stage of replication33. An alternative hypothesis is that replication-coupled repair, MMR, 
has lower efficiency in the late replicating regions35.  
 
Transcription level 
In cancer, transcription level has a strong effect on mutation rate. A study reported 
preneoplastic mutation rate in all types of cancer decreases with average transcription level at 
a hundred kilobase scale34. Apart from the strong effect of transcription, somatic mutations 
also exhibit an excess of A to G mutations on transcribed strand, a signature of TCR34,36. In 
noncancerous somatic tissues, transcribed genes show a lowered mutation rate compared to 
non-transcribed genes as well37,38. However, in sharp contrast to what is seen in somatic 
mutations, no clear effect of transcription is found in germline mutations22,39–42, except for 
one study that reported increased divergence between humans and macaques with greater 
germline expression43. To improve our understanding of the underlying mechanism of 
germline mutation and enable a cleaner comparison between germline and soma, I proposed a 
multivariate regression model which included these confounding factors as well as 
transcription level and examined the possible determinant factors and compared their effect 
sizes for these two types of tissues. 
 
1.3 Mutation pathogenicity 
1.3.1 Significance and challenges in genetic studies 
In clinical genetic testing, the main objective is to identify the genetic variants that cause 
human diseases, namely the pathogenic variants. Different from the functional impact on 
protein or damaging effect on fitness, pathogenicity refers to the likelihood of a variant to 
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cause disease in individual organism. Identification of pathogenic variants is critical for 
estimating recurrent risk and prognosis, facilitating preconception intervention, and 
sometimes lead to personalized treatment that may improve clinical outcome44. In addition, it 
can improve our understanding of the biology of the disease.  
With the advancing of high-throughput sequencing technologies, whole-exome or whole-
genome sequencing will soon become a routine part of medical genetics practice45,46, which 
leads to detection of a massive number of variants. Over three and a half million variants 
were detected in a study that sequenced the whole genome of a single individual, roughly 
equals to a thousand variants per megabase47.  
A common practice to identify risk genes or variants is association analysis where the 
frequency of a given variant is tested for significant differences between cases and controls. 
Mendelian diseases are assumed to be caused by a single variant with high penetrance and 
large effect size. These causal variants can be detected from the segregation patterns in 
familial sequencing studies. In polygenic diseases, multiple risk variants with relatively 
smaller effect size increase the disease susceptibility in an additive pattern. The latter 
normally requires a much larger sample size.  
Previous studies mostly focused on the discovery of common variants. However, these 
common variants cannot account for all the disease heritability48. The missing heritability 
may come from rare variants, the interactions between causal variants, environmental factors 
and so on. In the second part of this thesis, we focus explicitly on rare missense variants since 
missense variants are the most abundant protein-coding mutations in the human genome and 
contribute a variety of genetic common and rare diseases49,50. 
Protein coding variants can be divided into three categories, silent, missense and disruptive 
variants which lead to a relatively big change in the protein structure, such as nonsense, 
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frameshift, and splice site variants. Silent variants are assumed to be neutral with respect to 
its functional impact on the protein, whereas disruptive variants are regarded as deleterious. 
Missense variants which lead to a single amino acid change in the protein can be either 
neutral or deleterious. A number of published methods focused on the prediction 
deleteriousness at the variant level based on selection constrain such as CADD51 but fail to 
consider the gene dosage sensitivity that can modulate the pathogenicity of a deleterious 
variant50,52. For instance, hypomorphic variants are pathogenic only in the dosage-sensitive 
genes53. In this work, we aim to predict the pathogenicity which is the likelihood of a given 
variant to cause disease phenotype instead of deleteriousness at the protein level. 
 
1.3.2 Existing methods 
Many computational methods have been developed to predict whether a substitution will 
result in disease. They derive scores based on various features and define a threshold to 
assign the labels, benign, pathogenic, or uncertain. The early methods such as PolyPhen54, 
SIFT55, GERP56 and PhyloP57 tend to exploit a single information type such as protein 
function or conservation, whereas many of the recent algorithms are ensemble scores that 
integrate many diverse annotations into a single measure, such as CADD51, VEST 3.058, 
metaSVM59, M-CAP60, and REVEL61. A summary of these methods is shown in the table 
below (Table 1.1).
  




Table 1.1 Summary of existing methods 






Hidden Markov models 

















Naïve Bayes classifier 
Based on DNA sequence conservation, protein, splicing, 
polyadenylation etc. 
PolyPhen2_HDIV54 
Predict damaging  
effect 








Sum of amino acid substitution matrix  
score 




Sum of amino acid substitution matrix  
score 







Observation compared to null Multiple DNA sequence alignment 
PhastCons70 Hidden Markov models Multiple DNA sequence alignment of five vertebrate species 
PhyloP71 Hidden Markov models Multiple DNA sequence alignment 
Siphy72 Hidden Markov models 

















All 86 quantitative features in SNVBox including exon, 
transcript, amino acid, protein features etc. 
  
















Gradient boosting decision tree 
19 preexisting functional and 
conservation scores and 298 new 









Support Vector Machine 





Unsupervised eigen decomposition of 
covariance matrix 
Existing predictors such as SIFT, PolyPhen, GERP etc, and 
annotations such as population allele frequency, histone marks, 
transcription factor binding sites, open chromatin status 
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The performance of these ensemble algorithms is superior compared to that of the older ones 
and is more robust to technical artifacts, levels of constraint on genes, underlying disease 
mechanisms as evaluated by area under the receiver operating characteristic curve in ClinVar 
dataset76. However, when applied to recent de novo mutation data where the fraction of true 
positive is low (around 10% to 20%), these methods have limited performance with a low 
precision rate as shown in Table 1.2.  
Table 1.2 Estimated precision rate by published methods using recent de novo datasets   
Congenital heart disease 
(CHD) 
Autism spectrum disorder 
(ASD)  










All missense  N/A 264 0.17 264 0.13 
M-CAP > 0.025 219 0.26 202 0.18 
Meta-SVM > 0 115 0.31 105 0.22 
MutationTaster > 0.5 187 0.18 201 0.14 
PolyPhen > 0.5 170 0.22 183 0.17 
SIFT < 0.05 151 0.17 183 0.15 
VEST3 > 0.8 115 0.28 134 0.24 
CADD > 15 195 0.17 237 0.15 
REVEL > 0.5 133 0.33 162 0.3 
 
In addition, a circularity issue is involved during the evaluation of these methods because of 
the overlap between the training data used by a few predictors and the benchmark testing 
data. To provide a more accurate and systematic evaluation, an independent testing dataset 
not used by any existing predictors is of increasing importance. We therefore compiled 
cancer hotspot datasets and de novo mutation datasets. We designed a new prediction 
method, MVP to improve the prediction performance from two aspects. First, we built a deep 
learning model that is able to leverage large training data and capture rich sets of non-
linearity among features. In addition, we included gene-level features that describe the mode 
of action as explained in the previous section.  
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1.4 Thesis outline 
The remainder of this thesis will be organized into 2 chapters. 
In Chapter 2, we built a statistical framework to compare the determinant factors in germline 
and soma. To control for confounding effect of reported factors, we applied a multivariate 
regression model that included transcription level as well as other four factors, namely GC 
content, replication timing and two histone modification levels. We confirmed the effect of 
replication timing and revealed that the transcription level has an opposite effect on mutation 
rate in the two types of tissues. In addition, by looking at the strand asymmetry, we 
confirmed that transcription coupled repair operates in germline as well as somatic tissues.  
Taken together with the regression results, we suggested a clear difference of the balance of 
mutagenesis and repair in germline and soma. 
In Chapter 3, we described a new computational method that addresses the issue of predicting 
pathogenicity of missense variants. MVP used deep learning approach to leverage the large 
number of putative pathogenic variants from curated clinical databases. It was trained 
separately in constrained genes and non-constrained genes in order to take account of the 
difference in mode of action and genetic effort size of pathogenic missense variants. To 
provide an unbiased evaluation of our method, we compiled new testing datasets from cancer 
hotspot and de novo germline mutations from recent studies. Our method has superior 
performance compared to existing ones especially in non-constrained gene sets.  
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Chapter 2: Characterizing mutation rate 
variation and its mechanism in 
germline and soma 
This chapter is a paper published in Genetics: Chen, C., Qi, H., Shen, Y., Pickrell, J., & 
Przeworski, M. (2017). Contrasting Determinants of Mutation Rates in Germline and 
Soma. Genetics, 207(1), 255–267. http://doi.org/10.1534/genetics.117.1114 
My contribution to this project lies in preparation of all the datasets, statistical analysis of the 
determinant factors, strand asymmetry analysis as well as writing the draft, revisions and 
response to reviewers. 
2.1 Introduction 
Mutation rate varies along the genome from the scale of a single base pair to much larger 
scales14,22,77. Characterization of this variation and its determinants is of great importance to 
understand the underlying biological mechanism, such as mutagenesis and repair. At single 
base pair level, the largest source of variation in germline mutation rate is the identity of the 
adjacent base pairs78,22. Notably, the mutation rate of CpG transitions (henceforth CpG Ti) is 
an order of magnitude higher than other mutation types. Most CpG dinucleotides are 
methylated in the human genome in both germline and somatic tissues; when the methylated 
cytosine undergoes spontaneous deamination to generate thymine and is not corrected by the 
time of replication, the damage leads to a mutation. Among other types of sites, rates of 
mutation vary by 2 to 3 fold79. In the soma, the mutation rate at CpG sites is also elevated, 
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although the extent of the increase differs across tumor types36,80,81. More generally, tumors 
vary in their mutation spectrum: analyses of mutations and their two neighbouring base pairs 
(i.e., considering 96 mutation types) point to enrichment of distinct mutational signatures for 
different types of cancers, a subset of which have been shown to reflect particular mutagens 
or differences in the efficiency of repair82. 
Over a larger scale of megabases, germline mutation rates have been associated with a 
number of additional factors, including transcription level (in testis), replication timing (in 
lymphoblastoid cell lines), chromatin state (both in lymphoblastoid cells and in ovary), 
meiotic crossover rates and GC content 22,42,43,83–85. Somatic mutation rates have also been 
associated with replication timing (in Hela cell lines) and with average transcription levels 
across 91 cell lines in Cancer Cell Line Encyclopedia34. 
 
Figure 2.1 Correlation of mutation rate with expression level and replication time for all 
100 Kb windows across the genome.(Figure from Lawrence et al. 201334) 
 
In many cases, little is known about the mechanistic basis for the association of a given factor 
with mutation rates. However, the association of somatic mutation rates with transcription 
levels appears to be a by-product of transcription-coupled repair (TCR), a sub-pathway of 
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nucleotide excision repair (NER)86,87. NER is a versatile repair pathway that senses lesion-
causing distortions to DNA structure and excises the lesion for repair. Another sub-pathway 
of NER, global genome repair (GGR), can repair lesions on both transcribed strand 
(henceforth TS) and non-transcribed strand (henceforth NTS), including transcribed regions 
as well as transcriptionally-silent ones. In contrast, TCR operates only within transcribed 
regions, triggered by lesions on the TS, which it repairs off the NTS. This mechanism gives 
rise to a mutational strand asymmetry as well as a compositional asymmetry between strands. 
For example, TCR leads to more A to G mutations (A>G henceforth) on the NTS than TS; 
acting over long periods of time, this phenomenon generates an excess of G over A (and T 
over C) on the NTS19,39. Such mutational strand asymmetry has been found in both germline 
and soma34,41,42,88–90.  
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Figure 2.2 Transcription-coupled repair (TCR) pathway and global genome repair (GGR) 
pathways in mammalian cells (figure adapted from Hanawalt et al. 200886) 
 
While many of the same determinants appear to play important roles in both germline and 
soma, there are hints of differences as well. For instance, studies of pre-neoplastic somatic 
mutations indicate that, over a 100 kilobase (kb) scale, the mutation rates in somatic tissues 
decrease with expression levels and increase with later replication timing34. Similarly, two 
studies that focused on somatic mutations in non-cancerous somatic tissues, normal eyelid 
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tissue and neurons, found mutations to be enriched in regions of low expression and 
repressed chromatin37,88. A similar effect of replication timing was identified in studies of 
germline mutation28,33,42,84. However, the effect of expression levels on germline mutation 
rates remains unclear: one study reported increased divergence between humans and 
macaques with greater germline expression43, but others found no discernible effect of 
expression levels on mutation rates22,39–42. This difference between germline and soma is 
particularly puzzling in light of the observation that the strand asymmetry of mutation rates 
between TS and NTS is seen in the germline as well as the soma34,36,81,90. Together, these 
observations suggest that the determinants of mutation rates may differ between germline and 
soma, raising the more general possibility that the damage rate or the repair efficacy differs 
among cell types91.  
A limitation, however, is that studies have used different statistical approaches, rendering the 
comparison hard to interpret. As an illustration, whereas some studies binned the genome into 
windows of 100 kb34 or 1Mb regions92, other studies have compared the mean mutation rate 
in transcribed regions and non-transcribed regions or in genes grouped by expression 
levels37,42,77. Studies of somatic mutation also vary in whether they group different tissues or 
distinguish among them34,36. An additional limitation of earlier studies of germline mutation 
is that, by necessity, they relied on human-chimpanzee divergence as a proxy for de novo 
mutation rates22,39,40, even though divergence reflects not only the mutation process but also 
effects of natural selection in the human-chimpanzee ancestor and biased gene 
conversion19,93. 
To our knowledge, only one study has used a uniform approach to study germline and soma. 
Their findings point to possible differences in their determinants (Fig 2.3): for instance, the 
histone mark H3K9me3 accounts for more than 40% of mutation rate variation at 100 kb in 
tumors, when a much weaker association is seen in the germline30. This analysis relied on 
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pairwise correlations, however, and therefore the results may be confounded by other factors 
that are correlated to the histone marks and differ between tissues. Moreover, to our 
knowledge, there has been no parallel treatment of strand asymmetry in germline and soma. 
 
Figure 2.3 Pearson correlation between SNV density in germline germline or soma versus 
individual histone modification level. (Adapted from B S-Bockler et al. Nature 201230) 
 
To overcome these limitations, we built a multivariate regression model, in which the 
mutation rates of CpG transition (Ti) and other types of mutations in a coding region are 
predicted by GC content, expression levels, replication timing and two histone repressive 
marks. To this end, we used the expression levels, replication timing and histone marker 
levels of matched cell types, when available. We applied the model to a large set of germline 
point mutations identified in exomes from recently published studies on developmental 
disorders and to somatic point mutations in exomes found in four types of tumors and 
reported by the Cancer Genome. In addition, we considered the mutational strand asymmetry 
in the two sets of data. 
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2.2 Datasets and methods 
2.2.1 Germline mutation datasets 
To study germline mutations, we relied on de novo mutation calls made from 8681 trios 
surveyed by exome sequencing. We combined results from two main sources: studies of 
neurodevelopmental disorders (NDD), which considered 5542 cases and 1911 controls 
(unaffecteds), and studies of congenital heart defect (CHD), conducted by the Pediatric 
Cardiac Genomics Consortium, which included 1228 trios. The NDD cases include 3953 
cases of Autism Spectrum Disorder (ASD), 1133 cases of deciphering developmental 
disorders (DDD), 264 cases of epileptic encephalopathies (EE), and 192 cases of intellectual 
disability (ID). All these studies applied similar capture and sequencing methods, and most 
samples were at >20X coverage (Table 2.1).  
Table 2.1 Summary of germline datasets 
Datasets Trios References Capture Sequencing 
Autism Spectrum 
Disorder (ASD) 
3953 De Rubeis et al. 2014;  
Iossifov et al. 2014 
Exome Illumina and 
SOLiD 
Simons Simplex 
Collection, unaffected  
1911 Iossifov et al. 2014 Exome Illumina 
Congenital heart disease 
(CHD) 
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We tested for an effect of the study, which could potentially arise from differences in 
design or analysis pipeline, by adding a categorical variable (by an analogous approach to the 
one described below to test for differences among tissues). We found a marginally significant 
interaction between the study and the expression level in testis (our proxy for expression 
levels in the germline), driven by one study (CHD cases; Homsy et al. 2015), as well as for 
interactions between the studies and the effects of H3K9me3 and GC content, driven by two 
small studies (EE and ID) (Figure 2.4). Given these minor differences and in order to increase 
our power, we combined all the germline mutation datasets in what follows.  
Epileptic 
Encephalopathies (EE) 







192 de Ligt et al. 2012; Rauch 
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Figure 2.4 Coefficients of model testing for heterogeneity in the determinants of mutation 
rates among germline datasets. In panel A are results for CpG Ti and in panel B for other 
mutation types. Red, blue and green bars represent the 95% CI of the deviation of the 
estimated coefficient from that in the control (unaffected) group, shown for congenital heart 
defect (CHD), autism spectrum disorder (ASD), deciphering developmental disorder (DDD) 
datasets, intellectual disability (ID) and Epileptic Encephalopathies (EE), respectively. For all 
replication time data, a higher value means earlier. 
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2.2.2  Somatic mutation datasets 
To examine determinants of mutation rates in somatic tissues, we downloaded somatic 
mutation calls identified in four types of cancer from the Cancer Genome Atlas (TCGA) 
portal (in July 2015): breast invasive carcinoma (BRCA), cervical squamous cell carcinoma 
and endocervical adenocarcinoma (CESC), brain lower grade glioma (LGG), and liver 
hepatocellular carcinoma (LIHC). The numbers of samples are listed below (Table 2.2). In all 
cases, both non-cancerous and tumor tissues of patients were sampled and the exomes were 
sequenced using an Illumina platform. In the studies, mutation calls shared by the normal and 
tumor samples were removed (on the presumption that they are germline). What remains are 
somatic mutations found at high enough frequency to be seen in a large population of cells, 
which are therefore likely to predate the tumorigenesis, i.e., mutations that occurred in the 
pre-neoplastic tissues88. 
Table 2.2 Summary of somatic mutation datasets 
 
For each type of cancer with more than one mutation annotation file available in the 
TCGA data portal, we selected the file that included the largest number of patient samples. 
We removed the ~7.6% of samples that had an unusually large number of mutations per 
sample (p<0.05 by Tukey’s test), because they are likely to reflect loss of some aspect of the 
DNA mismatch repair and hence their mutational mechanisms likely differ35. 
Datasets Sample sizes 
Breast Invasive carcinoma (BRCA) 904 
Cervical squamous cell carcinoma and endocervical 
adenocarcinoma (CESC) 
181 
Low grade glioma (LGG) 502 
Liver hepatocellular carcinoma (LIHC) 171 
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2.2.3 Determinant factor datasets 
We considered the main factors previously reported to be significantly correlated with 
mutation rates, namely expression levels, replication timing, GC content and histone 
modification levels. To quantify expression levels, we relied on gene expression data 
(measured as RPKM) from the Genotype-Tissue Expression (GTEx) for breast, uterus, brain 
cortex and liver tissues. We also used GTEx expression data from testis and ovary tissues, as 
proxies for germline cells.  
The effect of the replication timing on somatic mutation rates was argued to be cell-type 
specific35. We therefore relied on Repli-Seq measurements (provided per base pair) in 
ENCODE cell lines that match the four types of cancer, namely MCF-7 (breast cancer), Hela-
S3 (cervical cancer), SK-N-SH (neuroblastoma), and HepG2 (liver hepatocellular carcinoma) 
cell lines. These measurements were obtained from the ENCODE website 
(https://www.encodeproject.org/search/?type=Experiment&assay_title=Repli-seq). In all 
cases, the replication timing reported is a smooth measure of the relative enrichment of early 
vs. late S-phase nascent strands, with high values indicating early replication. For each gene, 
we computed the average replication timing by taking the mean value of the data points that 
overlap with gene start-to-end coordinates in UCSC Refseq gene database. For genes with 
multiple transcripts, we took the union of all exons in all transcripts.  For germline mutations, 
there are no data for the appropriate cell types, so we used replicating timing estimates for 
lymphoblastoid cell lines (LCL) (provided in 10 kb windows)94. We also tried using 
replication timing data from three somatic tissues instead; the replication timing data are 
highly correlated among the tissues and accordingly the effects of mutation were estimated to 
be very similar. 
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In addition, we considered the effects of chromatin marks that had been shown to correlate 
individually with somatic and germline mutation rates28,30: specifically, histone modification 
H3K9me3 and H3K27me3, two repressive marks associated with constitutively and 
facultatively repressed genes, respectively. Levels of these marks were downloaded from 
roadmap epigenomics data browser (Dec 2015, hg19) 
(http://www.roadmapepigenomics.org/data/tables/all). We used the histone modification 
levels of adult ovary, breast myoepithelial cells, brain hippocampus and adult liver as proxies 
for germline, breast, brain and liver, respectively. In the following regression analysis, we 
considered only three of four somatic tissues, as we could not obtain histone modification 
data for CESC. Finally, we computed exonic GC content as the fraction of G or C residues in 
the union of exons in all isoforms of a given gene.  
Germline mutation studies relied on the UCSC Refseq gene annotation, whereas TCGA uses 
GENECODE annotation, which contains more transcripts95,96. To make the comparison 
cleaner, we focused on exonic regions considered in both types of studies by using gene and 
exon coordinates of Refseq database in build hg19 from UCSC genome browser. 
 
2.2.4  Statistical model 
Our main goal was to investigate possible relationships between mutation rates and gene 
expression levels, while controlling for replication timing, GC content and some histone 
modification levels. Because our mutation counts are over-dispersed, with greater variance 
than mean, we used a negative binomial regression model (instead of, e.g., a Poisson 
regression model). Specifically, for every protein-coding gene, we counted the number of 
CpG Ti or other types of mutations in the coding exons of a gene and treated it as an outcome 
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of a sequence of independent Bernoulli trials with probability λi, where λi is the probability 
of a mutation occurring in gene i.  
Transitions at CpG sites are thought to primarily occur due to spontaneous deamination at 
methylated cytosines, a distinct mutational source, and thus their determinants may be 
distinct from other mutation types14. However, within CpG islands, most CpGs are 
hypomethylated97 focus on a more homogeneous set of methylated CpGs, we therefore 
excluded CpG islands from the analyses of CpG Ti. CpG island annotations were 
downloaded from UCSC browser (track: CpG Islands). In one analysis, we included the 
average level of CpG methylation in each gene in our model, as assayed by bisulfate 
sequencing in ovary, sperm, ESC, breast myoepithelial cells, brain hippocampus cells, and 
adult liver cells. 
We considered gene expression levels measured in RPKM (X1), replication timing (X2), 
mean histone modification levels (H3K9me3 as X3, H3K27me3 as X4) and GC content (X5) 
as predictors. We also included L, the total number of CpG sites (when considering CpG Ti) 
or all nucleotides (when considering all other types of mutations) in the exons of the given 
gene, as an exposure variable, to account for the variation in gene length. The logarithm of λi 
is then modeled as a linear combination of these features scores: 
log(λi) =  β0 + ∑ βjXij
5
𝑗=1 + log(L) + ε 
We used R function glm.nb to estimate the coefficients, where β0 is an intercept term, βj is 
the effect size of feature j, and Xij is the score for feature j in gene i. In order to make the 
effect sizes of different features comparable within a model, we normalized all the predictor 
variables to have a mean of 0 and a standard deviation of 1. The gene expression levels 
measured in RPKM originally range from 0 to a few hundred thousand. As is standard39,94, 
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we added half of the smallest non-zero value in the corresponding expression data sets and 
then log-transformed the expression level before normalization. 
We note that in this model, we are considering possible effects one at a time. Including 
interaction terms affects the estimates and significance levels but changes none of the 
qualitative results, with the exception of results for H3K27me3, which become less 
significant (see Figure 2.5).  
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Figure 2.5 Comparing models with (blue) and without interaction terms (red). Panels A to H 
report results for CpG Ti and other mutation types in germline, BRCA (breast invasive 
carcinoma), LGG (brain lower grade glioma) and LIHC (liver hepatocellular carcinoma) data 
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sets, respectively. For all replication time data, a higher value means earlier. Bars denote 95% 
CI for the estimate of the regression coefficient. 
To examine whether the predictors have significantly different effects across tissues, we 
combined the models into one by including a categorical variable C for the tissue type. In this 
approach: 
C = 1 for somatic tissues, C = 0 for germline; 
log(λij) =  β0 + ∑ βjXij
5
𝑗=1
+ C (β6 + ∑ βjXij
11
𝑗=7
) + log(L) + ε 
X1, X2, X3, X4 and X5 are the same genomic or epigenomic features as in the separate model, 
β1, β2, β3, β4, β5 are the effect sizes of features X1 to X5 for testis, and β7, β8, β9, β10, β11 are the 
differences of effect size in the somatic tissue of features X1 to X5 compared to those in testis. 
We used the R function glm.nb to estimate the coefficients. 
Similarly, in order to ask whether effects differ between CpG Ti and other type of mutations 
in the same tissue, we included a binary variable C for the two mutation types. 
C = 1 for CpG Ti, C = 0 for all other mutations; 
log(λij) =  β0 + ∑ βjXij
5
𝑗=1
+ C (β6 + ∑ βjXij
11
𝑗=7
) + log(L) + ε 
All variables are set up the same way as in the combined model described previously, except 
for that β7, β8, β9, β10, β11 are now the differences of the effect sizes for CpG Ti compared to 
those for all other mutation types. 
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2.2.5 Mutation spectrum and strand asymmetry analysis  
We annotated the direction of transcription using the UCSC CCDS track and filtered out 
genes that are transcribed off both strands (1.7% of genes in Refseq), which left around 
19,000 genes to consider. This annotation allowed us to classify mutations into six types of 
mutation (A>C, A>G, A>T, G>A, G>C, G>T) on either TS or NTS. There are thus 12 
possible changes (each of the six on both strands). We then calculated the mutation rate of 
any given type on NTS and TS separately, by considering the number of corresponding 
mutations in the combined data sets, divided by the total number of nucleotides that could 
give rise to such a mutation in the exons. To obtain the confidence intervals on the mutation 
rates as well as for the mutation asymmetry ratio, we used bootstrap resampling. Specifically, 
we created 100 samples of the same size as the original sample, by drawing randomly from 
the original sample with replacement, and estimated the 95% CI from those 100 samples. 
We tested for strand asymmetry by a Chi-squared test. Because A>G strand asymmetry 
shows the greatest asymmetry (Green et al. 2003) and is the only mutation type that we found 
to be significant (and in the same direction) in all tissues, we focused primarily on this type, 
though we also considered A>T mutational patterns. To test if the extent of strand asymmetry 
changes with transcription levels, we grouped genes into expression level quantiles and 
calculated A>G strand asymmetry. Our measure of strand asymmetry is the ratio of the 
mutation rate on NTS to that on TS.   
We also considered the A>G mutation rates on NTS and TS). Here, the number of A>G 
mutations on NTS and TS for gene i is treated as an outcome of a sequence of independent 
Bernoulli trials with probability 𝜆𝑖 as the response variable in the model below. 
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where L is the corresponding number of As on the NTS or TS of a gene and other predictor 
variables are set up the same way as in the separate model. We applied the same analysis to 
A>T mutations, for which we detected significant asymmetry in the same direction in all 
types of tissues except for LGG. 
 
2.3 Result 
2.3.1 Determinants of mutation rate in germline and soma  
We began by applying our multivariable regression model (see Materials and Methods) 
to compare the determinants of mutation rates per gene between the two germline tissues and 
among the three somatic tissues (Figure 2.6). Results for germline mutations are very similar 
using testis or ovary expression profiles.  
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Figure 2.6 Coefficients of multivariable binomial regression model fit to germline and 
somatic mutation data. In panel A, are results for CpG Ti and in panel B, for other mutation 
types. Red, blue and green, purple and orange bars represent the 95% CI for the estimate of 
the regression coefficient in germline data set using ovary expression and testis expression, 
BRCA (breast invasive carcinoma), LGG (brain lower grade glioma) and LIHC (liver 
hepatocellular carcinoma) data sets respectively. For all replication timing data, a higher 
value means earlier. 
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Notably, in both testis and ovary, we found little effect of replication timing on 
germline mutation rates, other than a marginally significant negative effect for mutations 
other than CpG Ti (P=0.046, using testis expression data). An association of replication 
timing had been previously reported for (imperfect) proxies of de novo mutation rates 33, 
suggesting that our inconclusive findings may reflect lack of power. Indeed, if we combine 
all mutation types within a coding region and add CpG methylation levels within the gene as 
a covariate, the effect of replication timing is more readily apparent (Figure 2.7; P = 3.3x10-4 
using testes expression data and P=0.01 using ovary expression data).  
  
Figure 2.7 Coefficients of multivariable binomial regression model with DNA methylation 
levels added as a predictor, fit to germline and somatic mutation data. Red, blue and green, 
purple and orange bars represent the 95% CI for the estimate of the regression coefficient in 
germline data set using ovary expression and testis expression, BRCA (breast invasive 
carcinoma), LGG (brain lower grade glioma) and LIHC (liver hepatocellular carcinoma) data 
sets respectively. For all replication timing data, a higher value means earlier. 
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We also detected a significant increase of germline mutation rates with expression levels for 
both CpG Ti and other mutation types, in contrast to a previous study using de novo 
mutations42 and most previous studies of divergence. One difference with the previous 
analysis of de novo mutations is that we rely on exonic mutation data and focus on the unit of 
a gene, whereas they considered whole genome data, dividing it up into 100 kb windows.  
In our analysis, the effect of expression levels is most clearly seen using testis expression 
(e.g., in Figure 2.6, P = 2.1x10-6) rather than ovary expression (P = 0.02), possibly due to the 
fact that over three quarters of germline mutations are of male origin79,85,98. Alternatively, the 
ovary expression profile may be a poorer proxy for female germ cells than the testis 
expression profile is for male germ cells. In any case, henceforth, we use testis expression 
profile for analysis of the germline mutation rates, unless otherwise noted.  
We note that our analysis of germline mutation relies on de novo mutation calls made in 
exome studies of blood samples from six sets, including five cases and unaffected controls 
(see Table 2.1). A previous study reported that in one set of cases, individuals with congenital 
heart disease (CHD), there is an increased number of putatively damaging mutations in the 
genes most highly expressed in the developing heart and brainm99. Since the mutations are 
thought to be germline mutations (rather than somatic mutations), this association cannot be 
causal, instead reflecting an enrichment of damaging mutations in important heart 
developmental genes in CHD patients. To evaluate whether our findings of increased 
mutation rates with germline expression levels could be driven by a similar ascertainment 
bias, we excluded the CHD set and obtained the same results (see Figure 2.8). We also reran 
the analysis, comparing the effects in the five cases compared to the controls; none of the 
qualitative results differed, though as expected from the smaller size of the control sets, the 
estimated effect sizes were more uncertain (see Figure 2.9). Thus, our results suggest that the 
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increase in mutation rates with expression levels in testes is not a result of focusing primarily 
on cases. 
 
Figure 2.8 Coefficients of multivariable binomial regression model fit to germline mutation 
in four sets of cases excluding CHD. Red and blue bars represent the 95% CI for the estimate 
of the regression coefficient in CpG Ti and other mutation types, respectively. For all 
replication timing data, a higher value means earlier. 
 
 
      39 
 
Figure 2.9 Coefficients of model testing for heterogeneity in the determinants of mutation 
rates between cases and controls. In panel A are results for CpG Ti and in panel B for other 
mutation types. Red and blue bars represent the 95% CI of the estimated coefficient in the 
control (unaffected) group and all cases combined (ASD+CHD+DDD+EE+ID), respectively. 
For all replication timing data, a higher value means earlier. 
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Germline mutation rates involving CpG Ti and other types are negatively associated with 
H3K27me3 levels (Figure 2.7). We also found that, other than for CpG Ti, germline mutation 
rates increase with the GC content of a gene. This observation is consistent with previous 
findings of a high rate of GC to AT mutations relative to other types (e.g., Kong et al. 2012). 
In addition, it is thought that mis-incorporated bases during DNA replication in an AT-rich 
regions are more easily accessible and thus more easily repaired than GC rich regionsp100,101. 
Indeed, considering only AT sites, mutation rates increase in regions of higher GC (see 
Figure 2.10), indicating that there is an effect of the GC content of nearby sites, not only of 
the higher mutation rate of GC sites themselves. 
 
Figure 2.10 Coefficients of model fit to mutations at A or T base pairs. Red, blue, green, 
purple and orange bars represent the 95% CI of the regression coefficient using ovary 
expression and testis expression to predict germline mutation rates and BRCA (breast 
invasive carcinoma), LGG (brain lower grade glioma) and LIHC (liver hepatocellular 
carcinoma) to predict somatic mutation rates, respectively. For all replication timing data, a 
higher value means earlier. The model used here is the same as in Figure 2.6, but the offset 
term L is the number of A or T base pairs, rather than all base pairs. 
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Among somatic tissues, the effects of mutation rate predictors are also concordant. Notably, 
mutation rates decrease with expression levels in all three tissues, though the magnitudes of 
the effects differ. This finding is consistent with previous studies and thought to be a result of 
TCR34. Intriguingly, in a model comparing the effects on CpG Ti and other mutation types 
directly, in all three somatic tissues, the effect of expression levels on mutation rates is most 
pronounced for CpG Ti. This finding suggests that damage or repair of CpG Ti is tightly 
coupled to transcription. 
 
Figure 2.11 Regression coefficients from the combined model of CpG Ti and other 
mutations. In panel A are results for the germline using testis expression; in panel B, for 
breast tissue; in panel C, for brain tissue; and in panel D, for liver tissue. Black, blue and red 
bars represent coefficients for other mutations, coefficients for CpG Ti and the deviation of 
the estimated coefficient in CpG Ti from other mutations, respectively. Bars represent 95% 
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In all three somatic tissues, a later replication timing, a decrease in H3K27me3 levels, or an 
increase with H3K9me3 levels lead to an increase in mutation rates30,102,103. The effect of 
replicating timing on mutation rate has been attributed to the depletion of free nucleotides 
within later replicating regions, leading to the accumulation of single-stranded DNA and thus 
rendering the DNA more susceptible to endogenous DNA damage33. An alternative 
hypothesis is that DNA mismatch repair (MMR), which is coupled with replication, is more 
effective in the early replicating regions of the genome; this possibility is supported by the 
finding that this association is not detected in the tissue of MMR-deficient patients35. While 
on face value, it may seem surprising that replication timing is a significant determinant for 
the LGG samples, given that neurons are post-mitotic, glial cells still retain their ability to 
divide and a substantial fraction of mutations detected in neuronal samples may have 
occurred at earlier stages in development. 
 
2.3.2  Differences between germline and soma 
Figures 2.6 and 2.7 also hint at a difference between testis (and more tentatively, ovary) and 
somatic tissues in the magnitude of the effects of replication timing on mutation rates and the 
direction of the effects of expression levels, with a significant positive effect for germline 
mutations and a significantly negative effect for somatic tissues (e.g., BRCA: P = 8x10-16 for 
CpG Ti; P<2x10-16 for other mutation types; P< 2x10-7 for all somatic tissues and mutation 
types). When we tested for this difference explicitly, by adding a binary variable for soma 
and germline, we found that indeed, both expression levels and replication timing differ in 
their effects, for CpG Ti and other mutation types (using testis as a proxy for germline 
expression levels; Figure 2.12). The same qualitative results are obtained when using 
expression data from ovary instead (Figure 2.13).  
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Figure 2.12 Coefficients of combined model comparing each somatic data set to germline 
data set using testis expression. In panel A, results for CpG Ti and in panel B, for other 
mutation types. Red, blue and green bars represent the 95% CI of the deviation of the 
estimated coefficient from the germline estimate; they are shown for BRCA (breast invasive 
carcinoma), LGG (brain lower grade glioma) and LIHC (liver hepatocellular carcinoma) data 
sets respectively. For all replication timing data, a higher value means earlier. 
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Figure 2.13 Coefficients of combined model comparing each somatic data set to germline 
data set using ovary expression. In panel A, results for CpG Ti and in panel B, for other 
mutation types. Red, blue and green bars represent the 95% CI of the deviation of the 
estimated coefficient from the germline estimate; they are shown for BRCA (breast invasive 
carcinoma), LGG (brain lower grade glioma) and LIHC (liver hepatocellular carcinoma) data 
sets respectively. For all replication timing data, a higher value means earlier. 
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Notably, the effect of replication timing is stronger in soma (Figures 2.6 and Figure 2.12). 
The simplest explanation is that a larger fraction of mutations in the soma are introduced by 
errors related to replication, as opposed to other non-replicative sources. Another (not 
mutually-exclusive) possibility is that the effect of early replication versus late replication 
differs to a greater extent in the soma than in the germline. For example, if MMR is much 
more efficient in early replicating regions35 and more efficient in soma than germline. In 
addition, there is a significant difference between the effects of expression in testis and ovary 
compared to all three somatic tissues considered, with a greater decrease in mutation rates 
with expression seen in soma (Figures 2.6 and 2.12; Figure 2.13).  
 
2.3.3 Strand asymmetry in germline and soma 
To examine the underlying mechanism, we considered a signature of TCR—strand 
asymmetry—in the different tissues, detecting its presence among germline mutations as well 
as in all four somatic tissues (Figure 2.14). Consistent with previous studies 39,42,90, one type 
in particular, A > G, stands out. While the asymmetry is significant (and in the same 
direction) in all five data sets, with more mutation on the NTS than the TS, the extent of 
asymmetry is significantly different among the five data sets (2 test, P = 3x10-8; the ratios of 
the mutation rates on NTS vs TS are 1.66, 1.35, 1.25, 1.44 and 1.60 for germline, BRCA, 
CESC, LGG and LIHC, respectively). Intriguingly, other mutation types, notably G>C 
mutations, show even more pronounced differences among tissues, with significant excess on 
the transcribed strand in the germline and LGG samples but a significant paucity on the NTS 
in BRCA and CESC. These findings indicate a potential difference in either strand-biased 
damage or in TCR (or both) among somatic tissues. In summary, the total mutation rate 
appears to behave quite differently as a function of expression levels in testis and ovary 
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compared to soma (Figures 2.6, 2.12 and 2.13), despite the fact that we observed clear 
evidence for TCR in both germline and somatic mutations (Figure 2.14).  
 
Figure 2.14 Strand asymmetry for six mutation types. In panel A are results for the germline; 
in panel B, for BRCA (breast invasive carcinoma); in panel C, for CESC (cervical squamous 
cell carcinoma and endocervical adenocarcinoma); in panel D, for LGG (brain lower grade 
glioma); and in panel E, for LIHC (liver hepatocellular carcinoma). The error bars of the 
mutation rate denote 95% confidence intervals estimated by bootstrapping (see Methods). 
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One way to visualize these differences is to focus on A>G mutations and consider how the 
mutation rate and degree of strand asymmetry vary with expression in different tissues 
(Figure 2.15). A striking contrast emerges: in testis and ovary, as expression levels increase, 
mutation rates and asymmetry increase, whereas in the somatic tissues, asymmetry increases 
while mutation rates decrease. The same pattern is seen when A>T mutation rate and 
asymmetry are considered (see Figure 2.16). This difference in behavior with expression 
levels suggests that the balance between damage and repair rates during transcription differs 
between germline and soma.  
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Figure 2.15 The degree of A>G strand asymmetry and the A>G mutation rate as a function of 
gene expression level quartiles. Shown are in panels A and B are results for the germline 
using testis expression levels and ovary expression levels, respectively; in panel C, for BRCA 
(breast invasive carcinoma); in panel D, for CESC (cervical squamous cell carcinoma and 
endocervical adenocarcinoma); in panel E, for LGG (brain lower grade glioma); and in panel 
F, for LIHC (liver hepatocellular carcinoma). The error bars for both the strand asymmetry 
and the mutation rate per quartile were estimated by bootstrapping.  
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Figure 2.16 The degree of A>T strand asymmetry and the A>T mutation rate as a function of 
gene expression level quartiles. Shown are in panels A and B are results for the germline 
using testis expression levels and ovary expression levels, respectively; in panel C, for BRCA 
(breast invasive carcinoma); in panel D, for CESC (cervical squamous cell carcinoma and 
endocervical adenocarcinoma); in panel E, for LGG (brain lower grade glioma); and in panel 
F, for LIHC (liver hepatocellular carcinoma). The error bars for both the strand asymmetry 
and the mutation rate per quartile were estimated by bootstrapping. 
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To explore the effects of transcription in more depth, we applied our regression model to 
NTS A>G mutations and TS A>G mutations separately (Figure 2.17). Increased expression 
in the soma has no discernible effect on the NTS, other than in liver where it slightly 
increases mutation rates, but it decreases the mutation rate on the TS. In contrast, expression 
in testis and ovary leads to increased mutation rates on the NTS, and little or no elevation on 
the TS. Assuming there is no repair of the NTS by TCR, these findings indicate that 
transcription in the germline introduces greater damage than it does in the soma and in both 
cases that damage is efficiently repaired on the TS strand. If, however, the NTS is 
occasionally repaired by TCR or some other mechanism, then the findings indicate that the 
efficiency of TCR (relative to the damage rate) is greater in soma.  In this regard, we note that 
when the same analysis is applied to A>T mutations, which show significant asymmetry in 
all tissues considered other than LGG, there is some evidence that mutation rates decrease 
with expression in somatic tissues even on the NTS, suggesting some form of repair coupled 
to transcription (Figure 2.18). 
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Figure 2.17 Coefficients of the multivariable binomial regression model fit to A>G mutations 
on NTS (panel A) and TS (panel B). Red, blue, green, purple and orange bars represent the 
95% CI for the estimate of the regression coefficient in germline data set using expression 
levels in ovary, testis, BRCA (breast invasive carcinoma), LGG (brain lower grade glioma) 
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Figure 2.18 Coefficients of the multivariable binomial regression model fit to A>T mutations 
on NTS (panel A) and TS (panel B). Red, blue, green, purple and orange bars represent the 
95% CI for the estimate of the regression coefficient in germline data set using expression 
levels in ovary, testis, BRCA (breast invasive carcinoma), LGG (brain lower grade glioma) 
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and LIHC (liver hepatocellular carcinoma). For all replication timing data, a higher value 
means earlier. 
 
2.4 Conclusion and discussion 
We compared the determinants of mutation in the soma and the germline, using the same unit 
of analysis (a coding region) and the same statistical model, and applied it to similar exome 
data for germline de novo mutations and four types of tumors, in which mutations largely 
predate tumorigenesis. We recapitulated previous findings of the effects of GC content and of 
a histone mark indicative of repression on germline and somatic mutations, as well as those 
of expression levels and replication timing on somatic mutations30,34. Strikingly, we also 
found clear differences in the determinants of mutation rates between germline and soma, 
consistent with earlier hints based on divergence data22. Notably, our results confirmed that 
somatic mutation rates decrease with expression levels and reveal that, in sharp contrast, de 
novo germline mutation rates increase with expression levels in testis (and more tentatively, 
in ovary). This contrast suggests that transcription may be mutagenic in germline cells but not 
in soma, and that the DNA damage or repair processes differ between them. 
One limitation of our comparison—and of previous studies of germline and somatic 
mutation—is the need to rely on proxies for determinants of interest, such as replication 
timing data from cancer cell lines instead of normal cells and, perhaps most importantly, the 
use of testis and ovary as a proxy for germ cells. One difficulty in that regard is that so-called 
“germline mutations” actually arise from many stages of development, including cell types 
that predate the specification of the germline98 and thus it is difficult to know which of the 
available tissues to use as a proxy. Until these findings can be revisited with expression data 
from more precise cell types, such as primordial germ cells and spermatocytes, all that can be 
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concluded is that our findings point to a difference between somatic tissues and some subset 
of germ cells. 
A second limitation is that we considered only two types of mutations (CpG Ti and other). 
While these two types capture most of the variation in mutation rates, the larger context 
(adjacent base pairs, but also 7mers) also impacts mutation rates22,78,104. These different 
mutation subtypes are likely affected somewhat differently by the determinants considered 
here28. Despite these limitations, our work provides a framework to contrast possible 
determinants of mutation rates in soma and germline while controlling for some confounding 
effects, and results will only improve as data sets increase and the measurements of salient 
genomic and cellular features become more accurate.  
What is already clear is that there exist divergent effects of expression on mutation rates 
across tissues that are not attributable to well-known covariates. Moreover, the differences 
cannot readily be explained by the noise introduced by imperfect proxies or limited data. One 
possibility is that the effects of transcription do not vary across tissues but are non-linear in 
their effects on mutation rates. As a thought experiment, if genes that are not expressed were 
not repaired and had a relatively high mutation rate as a result and genes that are highly 
expressed had a high mutation rate because the repair efficiency is insufficient relative to 
damage, then genes with low levels of expression would be the least mutagenic. If so, tissues 
in which many genes have either low or no expression might show a decrease of mutation 
rates with expression, whereas tissues with many genes that are lowly or expressed might 
show an increase in mutation rates with expression.  
A more likely explanation, in our view, is that the trade-off between damage and repair 
associated with transcription differs among tissues, and in particular between germline and 
soma. Indeed, we know that tissue differs by sources of damage105 and the rate at which 
mutations accumulate103. There also exist differences in the signatures of strand asymmetry 
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(Figure 2.14). Transcription plausibly increases the rate of damage by opening up the DNA 
helix, rendering the single strands more susceptible to mutagens41,106. One possibility is that, 
in the germline, transcription-associated mutagenesis (TAM) swamps TCR, leading to higher 
mutation rates with increased transcription, whereas in the soma, TCR is more efficient, 
especially on the TS, and the balance of TAM and TCR leads to decreased mutagenesis with 
increased expression. Another possibility, which is not mutually exclusive, is the presence of 
additional repair mechanisms in somatic tissues. In support of this possibility, global genome 
repair (GGR) is attenuated in differentiated cells, yet mutations on the NTS appear to 
nonetheless be repaired efficiently107,108. This evidence led to the hypothesis of transcription-
domain-associated repair (DAR), which might repair damage on both strands in addition to 
TCR107 . From an evolutionary standpoint, the increased efficiency of TCR relative to TAM 
in soma versus germline may be explained by selection pressure on the repair of somatic 
tissues to prevent aging and cancer91.  
Mounting evidence suggests that per cell division mutation rates differ across tissues18,82,91 
and in particular that they may be higher in early embryonic development than at other stages 
of development14,98,109,110. This study raises the possibility that at least part of the explanation 
may lie in the balance between damage and repair, with TCR operating at different 
efficiencies relative to TAM or jointly with other repair pathways, thereby maintaining low 
mutation rates in soma. As mutation data from more tissues become available, it will be both 
feasible and enlightening to examine tissue-specific differences in repair.  
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Chapter 3: Mutation interpretation by deep 
learning method 
This chapter is a paper submitted to BioRxiv and is under review at Nature Communication:  
MVP: predicting pathogenicity of missense variants by deep neural networks 
Hongjian Qi*, Chen Chen*, Haicang Zhang*, John J Long, Wendy K Chung, Yongtao 
Guan, Yufeng Shen, bioRxiv 259390; doi: https://doi.org/10.1101/259390 
My contribution to this project lies in model performance optimization, feature and data sets 




One of the missions of clinical genetic studies is to identify risk variants responsible for 
diseases. Among all variants discovered by recent exome and genome sequencing studies, a 
majority of them are rare missense variants. These play major roles in disease causation and 
might contribute to the missing heritability in genome-wide association studies. However, 
most variants discovered by next generation sequencing studies are classified as variants of 
uncertain significance (VUS). On one hand, it’s not feasible to conduct experimental 
validation on all variants in such large numbers with the purpose of identifying causal 
variants. On the other hand, association studies require large sample sizes to detect rare 
variants with modest effect sizes with high statistical power. It’s thus essential to develop 
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computation tools to accurately predict the pathogenicity of rare missense variants to help 
prioritize those variants. 
Previously published in silico prediction methods have facilitated the interpretation of 
missense variants, such as CADD111, VEST3112, metaSVM113, M-CAP60, and REVEL61. 
CADD, the first ensemble score, integrated 63 distinct variant annotations and trained an 
SVM model with linear kernel based on population variants and expectation to predict variant 
deleteriousness. MetaSVM, M-CAP and REVEL are three scores widely adopted by 
clinicians. They applied SVM, gradient boosting decision tree and random forest as their 
model respectively. These models integrated both functional and conservation scores for 
pathogenicity prediction and were trained and tested on synthetic datasets which contained 
substantial fraction of false positives. The most recent one, MPC, used a logistic regression to 
classify novel variant based on synthetic regional constraint score, PolyPhen-2 and amino 
acid substitution badness score. These methods all adopt the same fundamental form: 
evaluation of variant features to derive a pathogenicity likelihood score and recommend a 
threshold to define pathogenic variant to balance between the precision and recall. However, 
all existing methods, as will be shown, have unacceptable high false positive rate. Based on 
recent de novo mutation data, they all have limited performance with low positive predictive 
value (Table 3.1), especially in non-constrained genes (defined as ExAC pLI<0.5).  
 
Table 3.1 Estimated number of pathogenic missense de novo mutations using published 
methods by recommended thresholds. The table indicates their thresholds, estimated number 
of risk variants and positive predictive values in Congenital heart disease and Autism 
spectrum disorder data. 
a) Evaluation among constrained genes (ExAC pLI≥0.5) 
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Congenital heart disease 
(CHD) 
Autism spectrum disorder 
(ASD)  










All missense  N/A 140 0.29 163 0.25 
M-CAP > 0.025 115 0.37 118 0.29 
Meta-SVM > 0 64 0.44 64 0.34 
MutationTaster > 0.5 102 0.25 134 0.23 
Polyphen  > 0.5 85 0.32 113 0.30 
SIFT < 0.05 90 0.29 107 0.24 
VEST3 > 0.8 83 0.44 96 0.39 
CADD > 15 106 0.27 147 0.26 
REVEL > 0.5 87 0.49 90 0.40 
 
b) Evaluation among non-constrained genes (ExAC pLI<0.5) 
  
Congenital heart disease 
(CHD) 
Autism spectrum disorder 
(ASD)  










All missense  N/A 124 0.12 101 0.07 
M-CAP > 0.025 104 0.20 84 0.11 
Meta-SVM > 0 50 0.23 40 0.14 
MutationTaster > 0.5 85 0.13 66 0.07 
Polyphen > 0.5 84 0.17 70 0.10 
SIFT < 0.05 61 0.11 76 0.09 
VEST3 > 0.8 31 0.14 38 0.12 
CADD > 15 89 0.12 90 0.09 
REVEL > 0.5 45 0.2 71 0.21 
 
Previous tools mostly relied on features such as functional predictors, conservation scores, or 
a combination of these metrics. Few metrics have yet taken advantage of protein domain 
knowledge such as protein post-translational modifications and protein secondary structure 
prediction. Given that the functional effect of a missense variation is tied to the domain 
disrupted by the variant, we hypothesize that incorporating these protein features will help 
improve the ability of our model to classify variants that play essential role as a key structural 
component or is involved in protein functional regulation by post-translational modifications. 
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Another sets of important features are gene mutation intolerance such as pLI50, lofz50, s-het114 
and domino115. Gene mutation intolerance, which reflects gene dosage sensitivity50,52 can 
modulate the pathogenicity of deleterious missense variants, as hypomorphic variants are 
pathogenic only in dosage-sensitive genes53. we hypothesize that incorporating these features 
will help improve the ability of our model to distinguish pathogenic variants from benign 
ones, especially in non-constrained genes. 
In addition to feature selection, previous tools are limited by the following two aspects. First, 
conventional machine learning approaches have limited capacity to leverage large amounts of 
training data compared to recently developed deep learning methods116. Second, databases of 
pathogenic variants curated from the literature are known to have a substantial rate of false 
positives52, which are likely caused by common issues across databases and therefore 
introduce inflation of benchmark performance. Developing new benchmark data and methods 
can help to assess and improve real performance.  
Based on these ideas, we developed a new model, MVP, which is based on a deep residual 
neural network to improve missense variant pathogenicity prediction. MVP incorporated 
additional features such as protein structure, interaction and modification scores as well as 
gene mutation intolerance scores.  
 
3.2 Datasets and methods 
3.2.1 Training datasets 
We compiled 22,390 missense mutations from Human Gene Mutation Database 
Pro version 2013 (HGMD)1 database under the disease mutation (DM) category, 
12,875 deleterious variants from UniProt59,117, and 4,424 pathogenic variants from 
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ClinVar database118 as true positive (TP). In total, there are 32,074 unique positive 
training variants. The negative training sets include 5,190 neutral variants from 
Uniprot, randomly selected 42,415 rare variants from DiscovEHR database119, and 
39,593 observed human-derived variants51. In total, there are 86,620 unique negative 
training variants (Table 3.2). 
 
3.2.2 Testing datasets 
We used three categories of testing data sets (Table 3.2).  The three categories are: (a) 
Benchmark data sets from VariBench59,120 as positives and randomly selected rare variants 
from DiscovEHR database119 as negatives; (b) cancer somatic missense mutations located in 
hotspots from recent study121 as positives and randomly selected rare variants from 
DiscovEHR database as negatives; (c) de novo missense mutation data sets from recent 
published exome-sequencing studies122–124. All variants in (a) and (b) that overlap with 
training data sets were excluded from testing. 
We tested the performance in constrained genes (ExAC pLI ≥ 0.5) and non-constrained gene 
(ExAC pLI < 0.5) separately.  
To focus on rare variants with large effect, we selected ultra-rare variants with MAF <10-4 
based on gnomAD database to filter variants in both training and testing data sets. We applied 
an additional filter of MAF < 10-6 for variants in constrained genes in both cases and controls 
for comparison based on a recent study .
 





Table 3.2 Summary statistics of training and testing data sets 

















positive HGMD positive variants 22390 1058 9287 337 13103 721 
Uniprot positive variants 12875 1070 5487 332 7388 738 
Clinvar pathogenetic variants 4424 813 2335 341 2089 472 
Total unique positive variants 32074 1914 13791 647 18287 1268 
negative Uniprot negative 5190 3240 1606 954 3584 2286 
Human-derived changes 39593 11739 7255 2672 32338 9067 
Randomly selected DiscovEHR 
rare variants 
42415 14311 12976 4109 29439 10202 





VariBench dataset 3333 459 997 149 2336 310 
DiscovEHR rare variants 
excluded from training 
3486 2960 1035 885 2451 2075 
Cancer 
datasets 
Cancer hotspots  875 204 698 149 177 55 
DiscovEHR rare variants 
excluded from training 
8771 4801 6989 3229 1782 1572 
De novo 
datasets 
Cases Autism spectrum 
disorder (ASD) 
2133 1843 665 576 1468 1267 
Congenital heart 
disease (CHD) 
1530 1373 483 424 1047 949 
  





Controls Simons Simplex 
Collection unaffected 
siblings  
869 817 236 224 633 593 
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3.2.3  Deep learning model 
MVP is based on a deep residual neural network model (ResNet) for predicting 
pathogenicity using the predictors described above. The model (Figure 3.1) takes a 
vector of the ordered features as input, followed by a convolutional layer of 32 kernels 
with size 3 x 1 and stride of 1 (stepsize = 1), then followed by 2 computational 
residual units, each consisting of 2 convolutional layers of 32 kernels with size 3 x 1 
and stride of 1 and a rectified linear unit (ReLU) activation layer in between. The 
output layer and input layer of the residual unit is summed and passed on to a ReLU 
activation layer. After the two convolutional layers with residual connections, 2 fully 
connected layers of 320 x 512 and 512 x1 are used followed by a sigmoid function to 
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Figure 3.1 The ResNet neural network architecture of MVP. Building blocks are arranged as 
shown in the figure. Parameters and dimensions of input and output are indicated in the 
boxes. Blue boxes are convolutional filters, green boxes are ReLU activation, yellow boxes 
are addition of output from 2 layers, orange boxes are fully connected layers. 
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In training, we randomly partitioned the training data sets into two parts, 80% of the total 
training sets for training and 20% for validation. To preserve the structured features in the 
training data, we ordered the features according to their correlations. We trained the model 
with a batch size of 64, used the adam57 optimizer to perform stochastic gradient descent58 
with logarithmic loss between the predicted value and true value. After one full training cycle 
on the training set, we applied the latest model weights on validation data to compute 
validation loss.  
To avoid over fitting, we used early stopping regularization during training. We computed the 
loss in training data and validation data after each training cycle and stopped the process 
when validation loss is comparable to training loss and do not decrease after 5 more training 
cycle, and then we set the model weights using the last set with the lowest validation loss. We 
applied the same model weights on testing data to obtain MVP scores for further analysis.  
 
3.2.4 Features  
MVP uses many correlated features as predictors (Table 3.3). There are six categories: 
(1) local context: GC content within 10 flanking bases on the reference genome; (2) amino 
acid constraint, including blosum62 and pam250126; (3) conservation scores, including 
phyloP 20way mammalian and 100way vertebrate127, GERP++56, SiPhy72, and phastCons 
20way mammalian and 100way vertebrate57; (4) protein structure, interaction, and 
modifications, including predicted secondary structures128, number of protein interactions 
from the BioPlex 2.0 Network129, whether the protein is involved in complexes formation 
from CORUM database130, number of high-confidence interacting proteins by PrePPI131, 
probability of a residue being located at the interaction interface by PrePPI (based on PPISP, 
PINUP, PredU), predicted accessible surface areas were obtained from dbPTM132, SUMO 
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scores in 7-amino acids neighborhood by GPS-SUMO133, phosphorylation sites predictions 
within 7 amino acids neighborhood by GPS3.013410/8/2018 9:59:00 AM, and ubiquitination 
scores within 14-amino acids neighborhood by UbiProber135; (5) Gene mutation intolerance, 
including ExAC metrics50 (pLI, pRec, lof_z) designed to measure gene dosage sensitivity or 
haploinsufficiency, RVIS136, probability of causing diseases under a dominant model 
“domino”115, average selection coefficient of loss of function variants in a gene “s_het”114, 
and sub-genic regional depletion of missense variants73; (6) Selected deleterious or 
pathogenicity scores by previous published methods obtained through dbNSFPv3.3a137, 
including Eigen75, VEST358, MutationTaster66, PolyPhen254, SIFT55 , PROVEAN67, fathmm-
MKL138, FATHMM138, MutationAssesso65, and LRT64. 
 
Table 3.3 Features in the MVP model 









local context GC content Yes Yes 
amino acid 
constraint  
blosum62 Yes Yes 
pam250 Yes  
conservation  
GERP++ RS rankscore Yes  





















SUMO_score Yes Yes 
phospho_score Yes Yes 
secondary_E Yes Yes 
secondary_H Yes Yes 
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secondary_C Yes Yes 
complex_CORUM Yes Yes 
preppi_counts Yes Yes 
ASA Yes Yes 
interface Yes Yes 
ubiquitination Yes Yes 







regional missense constraint Yes  
RVIS  Yes 
lof_z Yes Yes 
pRec Yes Yes 
pLI  Yes Yes 
domino  Yes 






Eigen-PC-raw rankscore Yes  
Eigne-PC-phred rankscore Yes  
Eigen-phred rankscore Yes Yes 
VEST3 Yes  
MutationTaster rankscore Yes  
Polyphen2 HVAR rankscore Yes  
Polyphen2 HDIV rankscore Yes  
SIFT rankscore Yes  




FATHMM rankscore Yes Yes 
MutationAssessor rankscore Yes  
LRT rankscore Yes  
 
For consistency, we used canonical transcripts to define all possible missense variants73. 
Missing values of protein complex scores are filled with 0 and other features are filled with -
1. 
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Since pathogenic variants in constrained genes and non-constrained genes may have different 
mode of action, we trained our models on constrained and non-constrained variants 
separately with different sets of features (38 features used in constrained model, 21 features 
used in non-constrained model, Table 3.3).   
 
3.2.5  Model evaluation 
Normalization of scores using rank percentile 
For each method, we first obtained predicted scores of all possible rare missense 
variants in canonical transcripts, and then sort the scores and converted the scores into 
rank percentile. Higher rank percentile indicates more damaging, e.g., a rank score of 
0.75 indicates the missense variant is more likely to be pathogenic than 75% of all 
possible missense variants.  
 
ROC curves and optimal threshold 
We plotted receiver operating characteristic (ROC) curves and calculated Area Under the 
Curve (AUC) values in training data with 6-fold cross validation, and compared MVP 
performance with other prediction scores in curated benchmark testing datasets and cancer 
hotspot mutation dataset. For each prediction method, we varied the threshold for calling 
pathogenic mutations in a certain range and computed the corresponding sensitivity and 
specificity based on true positive, false positive, false negative and true negative predictions. 
ROC curve was then generated by plotting sensitivity against 1 – specificity at each 
threshold.  
We define the optimal threshold for MVP score as the threshold where the corresponding 
point in ROC curve has the largest distance to the diagonal line. Based on the true positive 
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rate and false positive rate at the optimal points in ROC curves, we can estimate the precision 
and recall in de novo precision-recall-proxy curves. 
 
Precision-recall-proxy curves 
Since de novo mutation data do not have ground truth, we used the excess of predicted 
pathogenic missense de novo variants in cases compared to controls to estimate precision and 
proxy of recall. For various thresholds of different scores, we can calculate the estimated 
number of risk variants and estimated precision based on enrichment of predicted damaging 
variants in cases compared to controls. We adjusted the number of missense de novo 
mutation in controls by the synonymous rate ratio in cases verses controls, assuming the 
average number of synonymous as the data sets were sequenced and processed separately) 
(Table 3.4), which partly reduced the signal but ensures that our results were not inflated by 
the technical difference in data processing.  
 
Table 3.4 Comparison of cases and controls in rate of synonymous de novo variants 
 
Number of 
synonymous variants  
Rate per cases 
compared to controls  
Autism spectrum disorder (ASD) 1026 1.027 
Congenital heart disease (CHD) 701 1.049 




Denote the number of cases and controls as N1 and N0, respectively; the number of predicted 
pathogenic de novo missense variants as M1 and M0, in cases and controls, respectively; the 
rate of synonymous de novo variants as S1 and S0, in cases and controls, respectively; 
technical adjustment rate as 𝛼; and the enrichment rate of variants in cases compared to 
controls as R.  
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Then assuming the rate of synonymous de novo variants in cases and controls should 
be identical if there is no technical batch effect, we use 𝛼 to adjust estimated enrichment of 
pathogenic de novo variants in cases compared to the controls by:  







Then we can estimate number of true pathogenic variants (𝑀1













 Converting optimal point based on ROC into precision-recall like curve 
Denote the number of all true positives (pathogenic variants in cases) in a de 
novo mutation data set as P, the estimated number of true positive detected by all 
methods at any threshold (including estimation from “all missense” without prediction 
methods) as a set 𝒫, the number of all negatives (non-pathogenic variants in cases) in 
the de novo mutation data as N, the number of true positives by a method at a 
threshold as TP, the number of false positives by a method at a threshold as FP, and 
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1/?̂?  − 1
 
From the ROC curve, denote true positive rate (which is also called recall or 
sensitivity) as TPR, and false positive rate as FPR. We obtain FPR and TPR for a 
method at a certain threshold from cancer or VariBench ROC curves, and then use 
them to estimate number of true and false positives:  
𝑇?̂? = 𝑃 ∙ 𝑇𝑃𝑅 
𝐹?̂? = 𝑁 ∙ 𝐹𝑃𝑅 





























3.3.1 Feature preparation 
MVP uses many correlated predictors, which can be broadly grouped into two 
categories (Table 3.3): (a) “raw” features computed at different scales, per base pair (e.g. 
amino acid constraint score and conservation), per local context (e.g. protein structure and 
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modification) as well as per gene (e.g. gene mutation intolerance, sub-genic regional 
depletion of missense variants 17); (b) deleteriousness scores from selected previous methods. 
We reason that the variants in constrained genes (ExAC pLI≥0.5) and non-constrained genes 
(ExAC pLI<0.5) may have different modes of action of pathogenicity, therefore, trained our 
models for the two gene sets separately. We included 38 features for the constrained gene 
model, and 21 features for the non-constrained gene where we removed most published 
prediction methods features due to limited prediction accuracy (Table 3.3).   
The convolutional filters in the MVP model can exploit spatial locality by enforcing a local 
connectivity pattern between “neurons” of adjacent layers and identify nonlinear interactions 
at higher levels of the network. To take advantage of this characteristic, we ordered the 
predictors based on their correlation, as highly correlated predictors are clustered together 
(Figure 3.2). Notably, some protein-related predictors are weakly correlated with previous 
scores, suggesting that they may include additional information and can help improve the 
overall prediction accuracy. For each missense variant, we defined MVP score by the rank 
percentile of the ResNet’s raw sigmoid output relative to all 76 million possible missense 
variants.  
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Figure 3.2 Correlation and hierarchical clustering of features and additional published 
methods. We calculated pairwise Spearman correlation of all features and additional 
published methods across data points used in the training. Color key indicates absolute value 
of Spearman correlation coefficient among features and predictors. Columns are ordered by 
hierarchical clustering. Published methods marked with * are not used in training. 
 
3.3.2 Training result 
We obtained large curated datasets of pathogenic variants as positives and random rare 
missense variants from population data as negatives for training (Table 3.2). Using 6-fold 
cross-validation on the training set (Figure 3.3), MVP achieved mean area under the curve 
(AUC) of 0.99 in constrained genes and 0.97 in non-constrained genes.  
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Figure 3.3 Receiver operating characteristic (ROC) curves of MVP with 6-fold cross 
validation in the training dataset. (A) Performance evaluation in constrained genes (ExAC 
pLI ≥ 0.5). (B) Performance evaluation in non-constrained genes (ExAC pLI < 0.5). The 
performance of MVP in each fold is evaluated by the ROC curve and Area Under Curve 
(AUC) score indicated in parenthesis. Higher AUC score indicates better performance. 
 
3.3.3 Testing with labelled datasets 
To evaluate predictive performance of the MVP and compare it with other methods, we 
evaluated the performance in an independent curated testing dataset from VariBench10, 19 
(Figure 3.4). MVP outperformed all other scores with an AUC of 0.96 and 0.92 in 
constrained and non-constrained genes, respectively. A few recently published methods 
(REVEL, M-CAP, VEST3, and metaSVM) were among the second-best predictors and 
achieved AUC around 0.9.  
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Figure 3.4 Comparing MVP with previous methods by ROC curves using VariBench testing 
data. (A) Performance evaluation in constrained genes. (B) Performance evaluation in non-
constrained genes. The performance of each method is evaluated by the ROC curve and AUC 
score indicated in parenthesis. Higher AUC score indicates better performance. 
 
Systematic false positives caused by similar factors across training and VariBench data 
sets could inflate the performance in testing. To address this issue, we obtained two 
additional types of data for further evaluation. First, we compiled cancer somatic mutation 
data, including missense mutations located in inferred hotspots based on statistical evidence 
from a recent study20 as positives, and randomly selected variants from DiscovEHR21 
database as negatives. In this dataset, the performance of all methods decreased, but MVP 
still achieved the best performance of AUC of 0.91 and 0.85 in constrained and non-
constrained genes, respectively (Figure 3.5). We observed that methods using HGMD or 
UniProt in training generally have greater performance drop than others (Figure 3.6). 
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Figure 3.5 ROC curves for existing prediction scores and MVP scores of cancer somatic 
mutation data sets. (A) Constrained genes:  evaluation of 699 cancer mutations located in 
hotspots from 150 genes, and 6989 randomly selected mutations from DiscovEHR database 
excluding mutations used in training. (B) Non-constrained genes:  evaluation of 177 cancer 
mutations located in hotspots from 55 genes and 1782 randomly selected mutations from 
DiscovEHR database excluding mutations used in training. The performance of each method 
is evaluated by the ROC curve and AUC score indicated in parenthesis. Higher AUC score 
indicates better performance. 
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Figure 3.6 Comparison of AUC using VariBench data versus cancer mutation hotspots 
data for MVP and previous methods. X-axis indicates the AUC with VariBench data; y-axis 
indicates the AUC with cancer hotspots data. (A) comparison in constrained genes. (B) 
comparison in non-constrained genes. 
 
 
3.3.4 Testing with unlabelled de novo datasets 
To test the utility in real genetic studies, we obtained germline de novo missense 
variants (DNMs) from 2645 cases in a congenital heart disease (CHD) study2, 3953 cases in 
autism spectrum disorder (ASD) studies2, 4, 5, and DNMs from 1911 controls (unaffected 
siblings) in Simons Simplex Collection2, 4, 5. Since genes with cancer mutation hotspots are 
relatively well studied in both constrained and non-constrained gene sets, assessment using 
de novo mutations can provide additional insight with less bias (Table 3.6) 
    




Table 3.5 Number and percentage of genes in testing datasets that are overlapped with genes used in training 










































149 67 0.45 698 458 0.66 55 21 0.38 177 100 0.56 
ASD  874 151 0.17 1072 204 0.19 1359 183 0.13 1574 235 0.15 
CHD  640 103 0.16 746 142 0.19 1007 139 0.14 1112 164 0.15 
SSC control  372 59 0.16 406 68 0.17 641 77 0.12 683 87 0.13 
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We first compared the distribution of predicted scores of DNMs in cases with the ones 
in controls (Figure 3.8). Using Mann–Whitney U test, MVP-predicted scores of variants in 
cases and controls are significantly different (p=1e-5 and 2.7e-4 for CHD vs controls and 




Figure 3.7 Distribution of predicted scores of de novo missense variants by MVP and other 
methods. For each method, we normalized all predictions by rank percentile, and used Mann–
Whitney U test to assess the statistical significance of the difference between case controls. 
CHD: congenital heart disease; ASD: autism spectrum disorder; controls: unaffected siblings 
from the ASD study. Number of de novo missense variants compared: CHD: 1486; ASD: 
2050; controls: 838.  
 
We then calculated the enrichment rate of predicted pathogenic DNMs by a method 
with a certain threshold in the cases compared to the controls, and then estimated precision 
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and the number of true risk variants, which is a proxy of recall since the total number of true 
positives in all cases is a (unknown) constant independent of methods. We compared the 
performance of MVP to other methods by estimated precision and recall-proxy (Figure 3.9). 
Based on the optimal thresholds of MVP in cancer hotspot ROC curves, we used a score of 
0.7 in constrained genes and 0.75 in non-constrained genes to define pathogenic DNMs 
(Figure 3.9). In constrained genes, we observed an enrichment of 2.2 in CHD and an 
enrichment of 1.9 in ASD, achieving estimated precision of 0.55 and 0.47 (Figure 3.9A and 
3.9D), respectively. This indicates that about 50% of the MVP-predicted pathogenic DNMs 
contribute to the diseases. In non-constrained genes, we observed an enrichment of 1.5 in 
CHD and 1.4 in ASD respectively, and 0.33 and 0.28 in estimated precision (Figure 3.9B and 
3.9E). In all genes combined, MVP achieved an estimated precision of 40% for both CHD 
and ASD (Figure 3.9C and 3.9F). The next best methods reached 25% (M-CAP) and 20% 
(MPC) and REVEL) given the same recall-proxy for CHD and ASD, respectively.  
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Figure 3.8 Comparison of MVP and previously published methods using de novo missense 
mutations from CHD and ASD studies by precision-recall-proxy curves. Numbers on each 
point indicate rank percentile thresholds, star points indicate thresholds recommended by 
publications. The positions of “All Mis” points are estimated from all missense variants in the 
gene set without using any pathogenicity prediction method. The point size is proportional to 
–log (p-value). P-value is calculated by binomial test, only points with p value less than 0.05 
are shown. (A, B, C) Performance in CHD DNMs in constrained genes, non-constrained 
genes, and all genes, respectively. (D, E, F) Performance in ASD DNMs in constrained 
genes, non-constrained genes, and all genes, respectively. 
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3.3.5 Inflation of the performance in benchmark datasets 
The estimated precision of MVP with DNMs at optimal threshold is much closer to the 
expected precision based on ROC of cancer hotspots data than the value from VariBench data 
(Figure 3.10, 3.11), supporting that there is less performance inflation in testing using cancer 
data.   
 
Figure 3.9 Optimal threshold of MVP score based on ROC curve using cancer somatic 
mutation hotspots data.  Horizontal line and vertical line indicated the optimal threshold in 
which the ROC curve has the maximum distance to the diagonal line; (A) Constrained genes: 
MVP score 0.7 is best threshold; (B) Non-constrained genes: MVP score 0.75 is best 
threshold. 
 
A.   Constrained genes (pLI >= 0.5) B. Non-constrained genes (pLI < 0.5)
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Figure 3.10 Comparison of MVP and previous methods using de novo missense mutations 
from CHD and ASD studies by precision-recall-like curves. Numbers on each point indicate 
rank percentile thresholds; star points indicate thresholds recommended by publications. The 
position of “All Mis” points are estimated from all missense variants in the gene set without 
using any pathogenicity prediction method, black diamonds indicate estimated precision and 
number of variants from cancer hotspot ROC curve and VariBench ROC curve. The size of 
each point is proportional to –log(p-value). P-value is calculated by Binomial test, and only 
points with p-value < 0.05 are shown. (A, B) Performance in CHD de novo data in 
constrained genes and non-constrained genes, respectively. (D, E) Performance in ASD de 
novo data in constrained genes and non-constrained genes, respectively. 
A. Constrained genes (pLI >= 0.5) )                                        B. Non-constrained genes (pLI < 0.5)
C. Constrained genes (pLI >= 0.5) )                                       D. Non-constrained genes (pLI < 0.5)
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3.3.6 Feature contribution 
To investigate the contribution of features to MVP predictions, we performed cross-
one-group-out experiments and used the differences in AUC as an estimation of feature 
contribution Figure 3.7). We found that in constrained gene, conservation scores and 
published deleteriousness predictors have relatively large contribution, whereas in non-
constrained genes, protein structure and modification features and published predictors are 
most important.   
 
Figure 3.11 Measuring the contribution of features to MVP prediction performance in cancer 
mutation hotspots data. Performance contribution is measured by AUC reduction (ΔAUC) 
from excluding a group of features. Since features within a group is often highly correlated, 
we did measure the contribution of an entire group instead of individual features in the group. 
(A) Constrained genes; (B) Non-constrained genes. Error bar is estimated by subsampling of 
large number of negatives. 
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3.4 Conclusion and discussion 
In summary, we developed a new method, MVP, to predict pathogenicity of missense 
variants. MVP is based on residual neural networks, a supervised deep learning approach, and 
was trained using a large number of curated pathogenic variants from clinical databases on 
constrained genes and non- constrained genes separately. Using cancer mutation hotspots and 
de novo mutations from CHD and ASD, we showed that MVP achieved overall better 
performance than published methods, especially in non-constrained genes. Nevertheless, the 
fraction of pathogenic variants among de novo missense variants in non-constrained genes is 
low in both CHD and ASD, leading to relatively poor performance by all methods. MVP 
achieved substantially better performance than other methods in these genes, partly due to the 
inclusion of protein structure-based predictors.  
Further improvement in protein structure prediction and the utilization of protein structure in 
the model 22 would be the key to improve MVP. Finally, all methods are limited by the size 
and the potentially high false positive rate of the training data. Systematic efforts such as 
ClinVar23 will eventually produce better training data to improve prediction performance.  
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Chapter 4: Conclusions and future work 
4.1 Concluding Summary 
This thesis focuses on two aspects of protein-coding substitutions -- the generation of 
mutation and their fitness effect. In the first part of the thesis, we built a statistical framework 
to analyze determinant factors that cause mutation rate variation within a genome, which shed 
light on the mutagenesis and repair processes that lead to the generation of the mutations. 
More specifically, we built a multivariate regression model with five determinant factors, 
which include transcription level and factors that have been reported previously, namely GC 
content, replication timing and two histone marks. By applying the same model on the 
germline and somatic mutation data sets, we provided a clear answer to the long-standing 
question of whether the effect of transcription on mutation rate differs between the two types 
of tissue.  
In an improvement over previous studies, we directly used the pedigree sequencing data as 
the source of germline mutations instead of using divergence or diversity. Our result 
demonstrated that gene expression level has an opposite effect on the mutation rate of the 
two. Consistent with previous studies, we found that a higher expression level is associated 
with lower mutation rate in the soma after controlling for GC content, replication timing, and 
two histone marks. By contrast, genes with higher expression levels tend to have higher 
germline mutation rates. This indicates that, in the germ cells, the efficiency of mutagenesis 
swamps over that of repair processes during transcription, revealing the more mutagenic 
nature of transcription in germline. Since transcription-coupled repair (TCR) has been 
reported to help reduce the mutation load in somatic tissues, we examined strand asymmetry, 
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a signature of transcription-coupled repair (TCR), and found that it exists in both types of 
tissue but that the extent of stand asymmetry shows an opposite correlation with transcription 
confirming the differences between germline and soma. 
In the second part of the thesis, we developed a novel deep learning model to predict the 
pathogenicity of missense variants and prioritize them for genetic diagnosis and risk gene 
discovery. Our mode achieved better performance than previous methods in prioritizing 
pathogenic missense variants in three independent testing sets. One of the highlights of our 
model is that it takes advantage of additional features compared to previous models. Beyond 
features that describe the variant itself, gene level features such as gene dosage sensitivity 
play important roles in modulating the pathogenicity of the variant. Other features that 
contribute significantly to the improvement in performance is protein related features such as 
protein complex formation probability which can help identify pathogenic variants that are 
not destructive to the protein on which they are located but disrupt their interaction with 
others. We showed a cross-validation result that demonstrated that the performance of our 
model is not affected by the way we split our training dataset. To provide an unbiased 
evaluation of our methods and compare with others, we compiled new sets of testing data 
based on hotspot mutations in cancer and obtained more realistic performance measured in 
AUC. To demonstrate the utility of our model in real-world cases, we applied our method to 
congenital heart disease (CHD) and autism spectrum disorder (ASD) de novo mutation data 
and showed that it has superior performance compared to existing ones. We provided 
pathogenicity scores for all possible protein-coding variants along the genome, which can be 
used directly to assist with pathogenic variants identification as sequencing studies expand in 
scale. 
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4.2 Discussion and future directions 
The two methods we provided have a number of limitations that restrict their usefulness. 
First, both analyses are limited by the availability and the quality of data. Compared to 
previous studies, one advantage of our mutation process analysis is that we used more 
accurate mutation data from pedigree sequencing studies instead of human-chimpanzee 
divergence or SNP diversity. However, due to low de novo mutation rate and small sample 
size, it is very challenging for the model to capture the subtle differences among gene 
mutation rates. For instance, no mutation occurs in a substantial fraction of genes even 
though the mutation rate of these genes might be different. In addition, we only considered 
CpG and non-CpG mutations, which account for the most of the variation in mutation rates. 
Recent studies revealed that considering a larger context such as 3mer and 7mer would lead 
to the discovery of various determinants factors specific to each context and can account for a 
larger fraction of variations27,28. We also relied on proxies for determinant factors such as 
expression levels, epigenetic modification levels and replication timing. As continuing 
systematic efforts have been put into collecting various genomic and transcription data such 
as ENCODE139 and the Epigenome Roadmap140, our framework can be improved by 
incorporating more accurate data when available. Another concern in the mutation process 
analysis is that the transcriptome of the germ cells is constantly changing. Without knowing 
what fraction of mutations occur at different stages during germline development, it’s hard to 
decide which transcription data to use as the best proxy. When related data is available, it 
would be interesting to trace back the time at which each mutation occurs and build a more 
comprehensive model in a time-dependent manner.  
As for the pathogenicity prediction model, several features suffer from a high rate of missing 
values. For example, the protein-protein interaction data is based on known protein 
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complexes reported in literature and thus cannot account for all interactions in the proteome. 
An even more challenging problem for pathogenicity prediction is mislabelling issue in the 
training dataset. It is well known that the HGMD data set which is based on published 
literatures contains a substantial fraction of mislabelled pathogenic variants. Although we 
estimated that our model can tolerate as much as 20% of mislabelled training data, the 
prediction of variant pathogenicity could benefit a lot from a larger and more accurate 
training set.  
One of the next steps for mutation process analysis is to extend to mosaic mutations. These 
are early somatic mutations that may arise from a different process than cancer somatic 
mutations.  The mosaic mutation burden is around 0.2 per person in the protein-coding region 
based on around ten thousand trio exomes data from Krupp et al 2017141 and Hsieh et al 
(personal communication), which enable us to interrogate about one thousand mosaic 
mutations, a large enough sample to perform analysis on mutation process.  
For the future directions on the mutation impact prediction, we can improve gene-specific 
performance and clinical applications. The key difference between genetic study and clinical 
application is that the former is more about new risk gene discovery, while the latter is more 
about pathogenic variants in known risk genes. Our previous analysis of de novo mutations is 
mostly about new gene discovery. There are data sets on specific genes with some ground 
truth from massively parallel cellular function readout such as BRCA1, PTEN and TP53142,143. 
It provides us a great opportunity to modify and optimize our prediction model for genes of 
interest and resolve variants of uncertainty in clinical testing.  
The entire thesis focuses on the protein-coding substitutions in the human genome. It has 
been estimated that around 42% of the patients with severe developmental disorders can be 
attributed to pathogenic de novo mutations in protein-coding regions53. The remaining 
noncoding regions remain largely unexplored. Whole genome sequencing offers the 
    
     91 
opportunity to study the effect of various mutation process and the contribution of rare de 
novo mutations in the noncoding genome. With a large cohort and robust statistical methods, 
we can compare the mutation pattern between coding and non-coding regions and identify 
disease-associated regulatory elements. 
To sum up, we built unified and scalable frameworks capable of exploring the generation and 
fitness consequence of genetic variations in the human genome, which yield interesting 
biological insights. We anticipate that our framework and the precomputed pathogenicity 
score will be broadly useful and can be further improved or applied to cater to more specific 
needs when corresponding data is available.  
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